key: cord-0738460-intpv276
authors: Koh, Jasmine Shimin; De Silva, Deidre Anne; Quek, Amy May Lin; Chiew, Hui Jin; Tu, Tian Ming; Seet, Christopher Ying Hao; Hoe, Rebecca Hui Min; Saini, Monica; Hui, Andrew Che-Fai; Angon, Jasmyn; Ker, Justin Ruixin; Yong, Ming Hui; Goh, Yihui; Lim, Tchoyoson Choie Cheio; Tan, Benjamin Yong Qiang; Ng, Kay Wei Ping; Yeo, Leonard Leong Litt; Pang, Yu Zhi; Prakash, Kumar M.; Ahmad, Aftab; Thomas, Terrence; Lye, David Chien Boon; Tan, Kevin; Umapathi, Thirugnanam
title: Neurology of COVID-19 in Singapore
date: 2020-09-03
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.117118
sha: bfc29eabc23f144e72200c43a84c6c82493a4811
doc_id: 738460
cord_uid: intpv276

PURPOSE: To describe the spectrum of COVID-19 neurology in Singapore. METHOD: We prospectively studied all microbiologically-confirmed COVID-19 patients in Singapore, who were referred for any neurological complaint within three months of COVID-19 onset. Neurological diagnoses and relationship to COVID-19 was made by consensus guided by contemporaneous literature, refined using recent case definitions. RESULTS: 47,572 patients (median age 34 years, 98% males) were diagnosed with COVID-19 in Singapore between 19 March to 19 July 2020. We identified 90 patients (median age 38, 98.9% males) with neurological disorders; 39 with varying certainty of relationship to COVID-19 categorised as: i) Central nervous system syndromes-4 acute disseminated encephalomyelitis (ADEM) and encephalitis, ii) Cerebrovascular disorders-19 acute ischaemic stroke and transient ischaemic attack (AIS/TIA), 4 cerebral venous thrombosis (CVT), 2 intracerebral haemorrhage, iii) Peripheral nervous system-7 mono/polyneuropathies, and a novel group, iv) Autonomic nervous system-4 limited dysautonomic syndromes. Fifty-one other patients had pre/co-existent neurological conditions unrelated to COVID-19. Encephalitis/ADEM is delayed, occurring in critical COVID-19, while CVT and dysautonomia occurred early in relatively mild infection. AIS/TIA was variable in onset, occurring in patients with differing COVID-19 severity; remarkably 63.2% were asymptomatic. CVT was more frequent than expected and occurred in mild/asymptomatic patients. There were no neurological complications in all 81 paediatric COVID-19 cases. CONCLUSION: COVID-19 neurology has a wide spectrum of dysimmune-thrombotic disorders. We encountered relatively few neurological complications, probably because our outbreak involved largely young men with mild/ asymptomatic COVID-19. It is also widely perceived that the pandemic did not unduly affect Singapore healthcare system.

The 2003 Severe Acute Respiratory syndrome (SARS) outbreak, caused by SARS coronavirus-1 (SARS-CoV-1) resulted in 206 patients with 32 deaths in Singapore. Five patients developed large vessel stroke, largely attributed to the predilection for thromboembolism in critically ill SARS patients (1) . A study covering all adult and paediatric patients admitted to public hospitals during the 2009 H1N1 Influenza pandemic in Singapore (2) , identified 98 neurological complications developing at median of two days after onset. Majority were in patients less than 19 years old and the commonest disorder was seizures. Influenza associated encephalopathy occurred in 20%. A wider range of neurological conditions were seen among adults, half presenting with an exacerbation of their pre-existent neurological disease.

The current pandemic of a novel coronavirus SARS-CoV-2, causing the coronavirus disease 2019 has caused more than 15 million cases to date(3). Mao et. al. documented neurological manifestations in 36.4% (78/214) of COVID-19 patients(4). This was followed by reports of central and peripheral nervous systems (PNS) complications (5) (6) (7) , including anosmia, ageusia, headache, seizures, cranial neuropathies (8) , myelitis (9) , stroke(4-6,10,11), cerebral venous thrombosis (12) , encephalopathyencephalitis (4, 7, 10, 13, 14) and various neuropsychiatric manifestations (6) . Direct viral neurotropism has been reported rarely. Conversely, there have been increasing descriptions of secondary prothrombotic, dysimmune pathology (9, 13, (15) (16) (17) (18) and para-infectious phenomena such as Guillain-Barré (19, 20) syndrome (GBS). The exact incidence of neurological complications in COVID-19 patients is uncertain. The confounding effect of the surge in COVID-19 cases on healthcare systems has to be accounted for as published studies of COVID-19 neurology are largely from countries that have been overwhelmed by the pandemic (4, 7, 10) .

To comprehensively study the impact of COVID-19 on the nervous system, we set-up a multi-centre prospective database of all neurological disorders detected in microbiologically-confirmed COVID-19 patients.

We aim to describe the spectrum of COVID-19 neurology.

In this prospective multi-centre cohort study, we included patients with microbiologically-confirmed COVID-19 under the care of public healthcare institutions in Singapore (listed fully in author designations), who were referred for any neurological complaint within three months of COVID-19 diagnosis. COVID-19 was confirmed by a positive naso-or oropharyngeal swab for SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) and or raised SARS-CoV-2 IgG (21) . Severity of COVID-19 was defined (22) as: Mild: Nil or mild pneumonia; Severe: dyspnoea, tachypnoea and hypoxia requiring supplemental oxygen; Critical: Respiratory Pertinent clinical, laboratory and radiological data as well as final diagnosis were collated. Data was anonymised at entry and collected over a period needed to delineate fully the neurological diagnosis and its sequelae. We did not record anosmia and dysgeusia, common presenting complaints of COVID-19 , as specific neurological disorders. The study group tele-conferenced fortnightly to discuss the diagnoses and adjudicate their relationship to SARS-CoV-2 by consensus guided by contemporaneous literature. Subsequently, the certainty of association with COVID-19 was graded 'probable and 'possible' using the case definitions by Ellul et al (16) (see Appendix Table 1 ).The secondary aim of these sessions was to detect any trends that might have immediate impact on the management of COVID-19 patients. Several of the cases we describe (encephalitis, cerebral venous thrombosis, facial neuropathy, dysautonomia cases) have been previously submitted for publication as case reports/series by their managing physicians. As our aim is to comprehensively survey COVID-19 neurology in Singapore, we have chosen to include them and referenced them where applicable. The study was approved by the local institutional review board (CIRB 2020/2410).

Descriptive analysis is expressed as frequencies and percentages for categorical variables and median and range for continuous variables. 

Four critically-ill patients (age 40-73 years, all males) developed severe encephalitis. They were noted to be persistently encephalopathic when weaned-off sedation, at a median interval of 24 (15-65) days into illness, while recovering from critical COVID-19 that was complicated by sepsis, acute respiratory distress syndrome (ARDS) and renal failure. Case 1 was treated for COVID-19 with convalescent plasma, Case 2 and 3 with interferon beta 1b and lopinavir/ritonavir and Case 4 with remdesivir. Case 1's neurology was remarkable for spastic quadriparesis and transient ocular flutter, Case 3 had two episodes of right and left hemiplegia while Cases 2 and 4 had no focal neurological deficit. Case 1's cerebrospinal fluid (CSF) was remarkable for mild pleocytosis (red blood cells 22/µL and white blood cells 6/µl) and raised protein 0.56g/L , while Case 2's was normal. CSF SARS-CoV-2 RT-PCR was negative in both; viral culture and CSF SARS-CoV-2 serology were negative for Case 1. Cases 3 and 4 did not have CSF examined. MRI brain scans for Cases 1-3 showed multifocal abnormalities predominantly in the cerebral white matter, with varying involvement of the grey matter, brainstem and spinal cord ( Table 1 ). The four patients also displayed blood markers, e.g. raised D-dimer, fibrinogen and lupus anticoagulant (LAC), of autoimmunity and hypercoagulability. Cases 1, 3 and 4 did not respond significantly to empirical, albeit delayed, therapy with intravenous immunoglobulin (IVIG), corticosteroids, corticosteroid-IVIG combination respectively. Case 2 eventually recovered, after three months of intensive physical therapy, with mild neuropsychiatric deficits in working memory, visuospatial-perceptual and planning abilities. He did not receive any specific immunomodulatory treatment. Case 3 died three months into illness.

Four cases of cerebral venous thrombosis (CVT) occurred in young men (age 27-38 years). Two patients had mild COVID-19 while two were asymptomatic. Only two of the four patients had raised inflammatory and procoagulant markers ( Table 1 ). Median interval between onset of COVID-19 and CVT was 2 (0-21) days. All patients had unilateral thrombosis of transverse and sigmoid sinuses. Thrombosis extended into the internal jugular vein in three, of whom one had near complete thrombosis of superior sagittal sinus and another suffered a temporal lobe haematoma. None had risk factors except for one with a concomitant undisplaced occipital bone fracture from an accidental fall. Three received anticoagulation while one was not anticoagulated due to concomitant subdural hematoma. Three patients recovered and one died despite anticoagulation.

Out of a total of 19 patients,16 had acute ischaemic stroke (AIS), including two patients with clinical features of stroke and no intracranial bleed on brain CT. MRI brain could not be done for these two patients years, all males] with radiologically-confirmed AIS (with MRI brain) are presented in Table 1 . Remarkably, five were small-vessel stroke, two of whom had abnormal prothrombotic markers. Median interval between onset of COVID-19 and all AIS/TIA cases was 34 (0-68) days; and for radiologically-confirmed AIS cases it was 14 (0-55) days. Intravenous thrombolysis was administered to one patient and mechanical thrombectomy was performed for two patients. One patient died.

Two men (age 64 and 60 years) had intracerebral haemorrhage (ICH). Both had critical COVID-19 with multi-organ failure requiring extracorporeal membrane oxygenation (ECMO) and abnormal coagulation from therapeutic heparin. The second case also had prothrombotic tendency (Table 1) 

Fifty-one cases [median age 36 (22-75) years, 46 males] were referred for neurological symptoms, eventually deemed due to either pre-existent or co-existent neurological disorders unrelated to COVID-19

(Appendix Table 2 ). All except one had mild or asymptomatic COVID-19.

We set out to prospectively describe the spectrum of COVID-19 neurology. We recorded 39 patients with neurological complications, out of 47,572 (0.08%) COVID-19 patients. There were no neurological complications reported in 81 paediatric patients. The total number of neurological cases associated with COVID-19 was small compared to other studies(4,6,10). This might be related to the peculiar demographics of the local outbreak that involved young healthy migrant workers in large crowded dormitories, many of whom were asymptomatic or had mild infection. It is also largely perceived that the pandemic did not overwhelm Singapore's healthcare system. Of the 19 AIS/TIA, four patients were classified as 'probable' COVID-19 associated, while fifteen were graded as 'possible', because of the presence of pre-existent or newly-diagnosed traditional vascular risk factors (16) .

Remarkably, we also encountered five small-vessel stroke (two of whom had prothombotic factors, Table 1 ), in contrast to the predominantly large vessel stroke reported in other studies (5, 11, 29, 30) . Thrombotic tendency of COVID-19, arising from SARS-CoV-2-induced inflammation and endothelial dysfunction (31) , is likely contributory albeit we detected commonly screened prothrombotic markers in only 2/4 'probable' and 7/15 'possible' cases. Likewise, only 2/4 CVT cases had demonstrable prothrombotic markers ( Table 1) .

The two ICH cases were likely ECMO-related, hence the association with COVID-19 was graded as 'possible' (16) . In a pooled review of COVID-19 ARDS patients, the mortality rate was higher in those who underwent ECMO (94.1% versus 70.9%). As in one of our cases, the excess mortality may be related to COVID-19 dysimmune-coagulopathy (32) .

Association of the seven PNS disorders with COVID-19 was ranked 'probable' (16) . COVID-19 associated dysautonomia was a novel finding in our study. One patient with hyperhidrosis and orthostatic tachycardia, and three others with ocular dysautonomia; occurring at median 8 days from COVID-19 onset. We posit COVID-19 as a cause of dysimmune, limited autonomic dysfunction, similar to post-infectious autonomic neuropathy seen in diphtheria. Accommodation difficulty, inverse Argyll-Robertson pupil and delayed, mainly cardiovagal autonomic dysfunction, as well as hyperhidrosis have been reported in diphtheria patients (33, 34) , where the pathology is post-infectious segmental demyelination (35) . As expected in dysimmune aetiology, this complication did not correlate with the severity of COVID-19. Dysautonomia was reported in 21 out of 841 COVID-19 patients in the ALBACOVID registry (10) . No details of their autonomic dysfunction were given but the authors also suggested dysimmune pathology.

We recorded 51 other cases with pre-or co-existent neurological disorders unrelated to SARS-CoV-2 (Appendix Table 2 ). Cognizant that COVID-19 is a novel disorder, we were wary of misattributing causality (16, 36) . These cases were adjudicated unrelated to SARS-CoV-2 after scrutiny of the temporal relationship of their symptoms to COVID-19 and likelihood of alternative aetiology. Seizure, headache, PNS disorders and functional neurological disorders (FND) were the main conditions. Similar to other cohorts (4,6,10), headache was not uncommon in our study. In addition, we saw eight patients with FND. While direct effects of the infection cannot be separated from psychosocial impact of the pandemic on underlying or reactive psychopathology, we believe prolonged isolation played an important role. Furthermore, we anticipated pandemic-induced disruption of medical services to increase unrelated neurological disorders and exaggerate the neurological morbidity of COVID-19. However, this accounted for only two patients -one with relapsed manic depressive disorder and another with epilepsy.

A recent editorial called for a better understanding of COVID-19 neurology(36). A major strength of our study is the inclusion of only microbiologically-confirmed COVID-19 cases. It is also a comprehensive nation-wide survey that included all COVID-19 patients in Singapore and prospectively analysed all their neurological complaints. Furthermore, extensive surveillance and case-finding of COVID-19 in Singapore allows us to be confident of the denominator against which the 39 neurological complications are contextualised. We acknowledge the following limitations. Our attribution of neurological complications to COVID-19, while based on standardized case definitions(16), was not guided by specific pathological evidence.

Restrictions from infection and movement control limited the evaluation of some patients. There was also referral bias. Although all COVID-19 patients in Singapore were isolated in hospitals or community care facilities that came under the care of the authors' institutions, some cases were likely missed. A number of patients with neurological disorders, presenting with symptoms such as encephalopathy and behavioural problems, may not have been referred by their primary physicians because they were deemed to have apparent non-neurological causes. There is also a tendency for clinicians to flag out more serious conditions and J o u r n a l P r e -p r o o f disorders already perceived to be related to COVID-19. Nevertheless, we believe we have captured the majority of neurological disorders occurring in this cohort of COVID-19 patients during the study period. Finally, the generalisability of our study is limited by the disproportionate number of young healthy males in our cohort.

COVID-19 neurology has a wide spectrum of distinct dysimmune-thrombotic disorders that can be 

None. This research did not receive any specific grant from funding agencies in the public, commercial, or notfor-profit sectors.

The study was approved by the Singapore Health Services institutional review board (CIRB 2020/2410). Waiver of consent was granted by the Singapore Health Services institutional review board.

Data is available upon reasonable request. All data relevant to the study are included in the article and supplemental material. Patient-related data will be shared upon request from any qualified investigator, maintaining anonymisation of the individual patients.

J o u r n a l P r e -p r o o f

Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium

Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

Guillain-Barr. syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

Guillain-Barré syndrome

An Updated Definition of Stroke for the 21st Century

Definition and Evaluation of Transient Ischemic Attack

Neurological associations of COVID-19

Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)

Neurology of the H1N1 pandemic in Singapore: a nationwide case series of children and adults

World Health Organization. The Coronavirus Disease 2019 (COVID-19):Situation report-36

Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

The international EAN survey on neurological symptoms in patients with COVID-19 infection

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Pearls and Oy-sters: Facial nerve palsy as a neurological manifestation of Covid-19 infection

COVID-19-associated acute necrotizing myelitis

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Characteristics of ischaemic stroke associated with COVID-19

Venous cerebral thrombosis in COVID-19 patient

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Neurological Associations of COVID-19

Neuropathology of COVID-19: a spectrum of vascular and J o u r n a l P r e -p r o o f acute disseminated encephalomyelitis (ADEM)-like pathology

COVID-19-associated acute disseminated encephalomyelitis (ADEM)

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?

Interpreting Diagnostic Tests for SARS-CoV-2

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Neuropathological Features of Covid-19

A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient

Cerebral Venous Sinus Thrombosis Incidence is Higher Than Previously Thought: A Retrospective Population-Based Study

Stroke epidemiology in south, east, and south-east asia: A review

Thrombosis of posterior condylar vein with extension to internal jugular vein; A rare radiological finding in traumatic brain injury

Singapore Stroke Registry Annual Report

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

SARS2-CoV-2 and Stroke in a New York Healthcare System

Endothelial cell infection and endotheliitis in COVID-19

Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports

Autonomic dysfunction in diphtheritic neuropathy

Diphtheritic polyneuropathy: Clinical analysis of severe J o u r n a l P r e -p r o o f forms

Diphtheritic polyneuritis-a pathological study

J o u r n a l P r e -p r o o f

 Table 1 Diagnostic criteria and case definitions for the association of neurological disorders with COVID-19 (MRI: Magnetic resonance imaging; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2 ; PCR: Polymerase chain reaction; CSF: Cerebrospinal fluid; CNS: Central nervous system; WHO: World Health Organization) (adapted from Ellul's et. al) (9) Appendix Table 2 J o u r n a l P r e -p r o o f